Portsmouth Technologies Sells 30 Lakh Anthem Biosciences Shares in Rs 250 Crore Block Deal

On October 9, Portsmouth Technologies LLC completed a substantial block deal by selling 30 lakh shares of Anthem Biosciences on the Bombay Stock Exchange (BSE). The shares were transacted at Rs 833 each, resulting in a total deal value of Rs 249.90 crore.

According to the latest BSE data as of June 30, 2026, Portsmouth Technologies held 1,53,96,327 shares, representing 2.73% of Anthem Biosciences' equity. The recent sale equates to nearly 19.49% of Portsmouth's holdings at that time. If there have been no other shareholding changes since June, Portsmouth’s stake would now be approximately 1,23,96,327 shares, though this figure awaits official confirmation from updated disclosures.

The identity of the purchaser in this block deal has not been disclosed. On the day of the transaction, Anthem Biosciences’ stock closed at Rs 861.35, down 1.33% from the previous close of Rs 873. The stock price fluctuated between Rs 833 and Rs 878.70 during the session, with the block deal price about 3.29% below the closing price.

Since the start of 2026, Anthem Biosciences’ shares have seen a significant rise of 34.80%, contributing to a current market capitalization of Rs 48,539.49 crore based on the closing price on October 9.

Anthem Biosciences recently reported its financial performance for the first quarter of fiscal year 2027 (FY27). The company recorded total revenue of Rs 443.11 crore, marking a 21.3% decrease compared to Rs 563.02 crore in the same quarter the previous year. Profit after tax also declined by 11.7%, falling to Rs 119.94 crore from Rs 135.79 crore year-over-year.

Further, the firm’s profit before tax dropped by 22.4% to Rs 144.58 crore from Rs 186.25 crore in the corresponding quarter last year. Earnings per share for the quarter stood at Rs 2.11, down from Rs 2.42 a year earlier.

Anthem Biosciences debuted on the stock market in July 2025 following an initial public offering (IPO) that was entirely an offer for sale by promoters and existing shareholders. The IPO included nearly 5.96 crore shares, valued at around Rs 3,395 crore at the issue price of Rs 570 per share. When the shares started trading on July 21, 2025, they opened at Rs 723.05 each, a premium of 26.85% over the IPO price.

As of October 9, trading at Rs 861.35, Anthem Biosciences shares were priced roughly 51.11% above the IPO issue price, reflecting investor confidence despite the recent quarterly earnings dip.

The pharmaceutical and biotech sectors in India have witnessed considerable interest from investors in recent years, driven by ongoing innovation and expanding markets. Anthem Biosciences operates within this dynamic environment, making its stock activity significant for market observers.

Portsmouth Technologies’ decision to reduce its holding in Anthem Biosciences highlights the fluid nature of shareholding patterns among institutional investors. Such block deals can influence stock liquidity and investor perception, underlining the importance of monitoring share transactions closely.

Investors and market participants are advised to review official disclosures and company announcements to stay informed about changes in shareholding and financial results. Understanding these developments helps in making informed decisions within India’s evolving equity markets.